Wellbutrin SR Patent Cases: Did GSK Surrender Claims To Excipients?

GlaxoSmithKline's patent infringement cases against Impax and Excel regarding Wellbutrin SR and Zyban appear to hinge on whether excipients used by the generic firms were "foreseeable.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet